Basic Stats
| LEI | 549300BRDKZ1HFI2J358 |
| CIK | 1757898 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to STERIS plc
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| August 7, 2025 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated August 7, 2025 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for the |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission Fil |
|
| August 6, 2025 |
STERIS Announces Financial Results for Fiscal 2026 First Quarter Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2026 First Quarter • Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% • As reported EPS from continuing operations increased to $1.79; adjusted EPS increased to $2.34 • Fiscal 2026 outlook updated DUBLIN, IRELAND - (August 6, 2025) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today an |
|
| August 6, 2025 |
Exhibit 99.2 STERIS Announces Chief Financial Officer Transition Long-time CFO Michael J. Tokich to be succeeded by Karen L. Burton, Chief Accounting Officer DUBLIN, IRELAND – August 6, 2025 - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that Michael J. Tokich, Senior Vice President and Chief Financial Officer (CFO), is stepping down from his role following seventeen years as |
|
| July 3, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only as permitted by Rule 14a-6(e)(2)) |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission File |
|
| June 25, 2025 |
Securities and Exchange Commission Washington, D. C. 20549 FORM 11-K Securities and Exchange Commission Washington, D. C. 20549 FORM 11-K ý Annual Report Pursuant to Section 15(d) of The Securities Exchange Act of 1934 For the Twelve Month Period Ended December 31, 2024 OR o Transition Report Pursuant to Section 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38848 A. Full title of the plan and the address o |
|
| June 12, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only as permitted by Rule 14a-6(e)(2)) |
|
| June 12, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| May 30, 2025 |
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT STERIS plc (Exact name of registrant as specified in its charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 70 Sir John Rogerson’s Quay, Dublin 2, Ireland DE21 6LY (Address of principal executiv |
|
| May 30, 2025 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 STERIS plc Conflict Minerals Report for the Reporting Period from January 1, 2024, to December 31, 2024 Introduction This Conflict Minerals Report is filed by STERIS plc (“STERIS”) for the reporting period from January 1, 2024 to December 31, 2024 (the “Reporting Period”) as Exhibit 1.01 to STERIS’s Form SD pursuant to the requirements of Rule 13p-1 of the Securities Exchange Act of 1 |
|
| May 29, 2025 |
United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-K United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38848 STERIS plc (Exact name of registrant as specified i |
|
| May 29, 2025 |
Exhibit 24.1 STERIS PLC POWER OF ATTORNEY FORM 10-K Each of the undersigned hereby makes, constitutes, and appoints Daniel A. Carestio, Michael J. Tokich, Karen L. Burton, and J. Adam Zangerle, and each of them, his or her true and lawful attorney, with full power of substitution, for and in his or her name, place, and stead, to affix, as attorney-in-fact, his or her signature in any and all capac |
|
| May 29, 2025 |
Exhibit 21.1 SUBSIDIARIES OF STERIS PLC STERIS plc has no parent company. As of March 31, 2025, its direct and indirect subsidiaries were as follows: Name Jurisdiction of Incorporation Albert Browne Limited England and Wales American Sterilizer Company Pennsylvania, USA Bioster-Mottahedoon Egypt SAE Egypt Birkova Products, LLC Indiana, USA Bizworth Gammarad Sdn Bhd Malaysia Black Diamond Video, In |
|
| May 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission File |
|
| May 14, 2025 |
STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year • Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% • Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22 • Fiscal 2026 outlook provided DUBLIN, IR |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission Fil |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| February 7, 2025 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated February 7, 2025 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for th |
|
| February 5, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission |
|
| February 5, 2025 |
STERIS Announces Financial Results for Fiscal 2025 Third Quarter Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2025 Third Quarter • Total revenue from continuing operations increased 6%; constant currency organic revenue grew 6% • As reported EPS from continuing operations increased to $1.75; adjusted EPS increased to $2.32 • Fiscal 2025 outlook updated DUBLIN, IRELAND - (February 5, 2025) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| November 7, 2024 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated November 7, 2024 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for th |
|
| November 7, 2024 |
Description of STERIS plc Non-Employee Director Compensation Program.* Exhibit 10.1 Description of STERIS plc Non-Employee Director Compensation Program Summarized below is the Director compensation program for STERIS plc (“STERIS”) non-employee Directors for the term of office beginning August 1, 2024. Director retainer fees have remained the same for the 2024-2025 term of office as for the prior term of office. An annual retainer of $323,000 is payable to each non- |
|
| November 6, 2024 |
STERIS Announces Financial Results for Fiscal 2025 Second Quarter Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2025 Second Quarter • Total revenue from continuing operations increased 7%; constant currency organic revenue grew 7% • As reported EPS from continuing operations increased to $1.51; adjusted EPS increased to $2.14 • Fiscal 2025 outlook reiterated DUBLIN, IRELAND - (November 6, 2024) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) to |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| October 7, 2024 |
Exhibit 10.1 $1,100,000,000 CREDIT AGREEMENT Dated as of October 7, 2024 among STERIS PLC, as a Borrower, STERIS LIMITED, as a Borrower, STERIS CORPORATION, as a Borrower, STERIS IRISH FINCO UNLIMITED COMPANY, as a Borrower, The Guarantors Party Hereto, VARIOUS FINANCIAL INSTITUTIONS, as Lenders, and JPMORGAN CHASE BANK, N.A., as Administrative Agent BOFA SECURITIES, INC., CITIBANK, N.A. PNC BANK, |
|
| August 8, 2024 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated August 8, 2024 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for the |
|
| August 8, 2024 |
EQUITY PURCHASE AGREEMENT AMONG STERIS CORPORATION, HUFRIEDY GROUP HOLDING LLC AND SOLELY WITH RESPECT TO SECTION 2. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission Fi |
|
| August 6, 2024 |
STERIS Announces Financial Results for Fiscal 2025 First Quarter Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2025 First Quarter • Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6% • As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03 • Fiscal 2025 outlook reiterated DUBLIN, IRELAND - (August 6, 2024) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| June 21, 2024 |
Securities and Exchange Commission Washington, D. C. 20549 FORM 11-K Securities and Exchange Commission Washington, D. C. 20549 FORM 11-K ý Annual Report Pursuant to Section 15(d) of The Securities Exchange Act of 1934 For the Twelve Month Period Ended December 31, 2023 OR o Transition Report Pursuant to Section 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38848 A. Full title of the plan and the address o |
|
| June 12, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only as permitted by Rule |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT STERIS plc (Exact name of registrant as specified in its charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 70 Sir John Rogerson’s Quay, Dublin 2, Ireland DE21 6LY (Address of principal executive o |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em |
|
| May 31, 2024 |
Exhibit 1.01 STERIS plc Conflict Minerals Report for the Reporting Period from January 1, 2023 to December 31, 2023 Introduction This Conflict Minerals Report is filed by STERIS plc (“STERIS”) for the reporting period from January 1, 2023 to December 31, 2023 (the “Reporting Period”) as Exhibit 1.01 to STERIS’s Form SD pursuant to the requirements of Rule 13p-1 of the Securities Exchange Act of 19 |
|
| May 29, 2024 |
Exhibit 21.1 SUBSIDIARIES OF STERIS PLC STERIS plc has no parent company. As of March 31, 2024, its direct and indirect subsidiaries were as follows: 1666 E Touhy LLC Illinois Accelera Technologies, LLC Minnesota Accutron, Inc. Arizona Albert Browne Limited England and Wales American Sterilizer Company Pennsylvania Bioster-Mottahedoon Egypt SAE Egypt Birkova Products, LLC Indiana Bizworth Gammarad |
|
| May 29, 2024 |
STERIS plc Insider Trading Policy Exhibit 19.1 STERIS plc Insider Trading Policy BCP-10.2 Version # Effective Date Page 1 of 18 3 May 3, 2023 Purpose: The purpose of this Insider Trading Policy is to promote compliance with applicable securities laws by the Company and its subsidiaries and all directors, senior managers (including any manager who would be considered an “officer” as such term is defined under Rule 16a-1 of the Exch |
|
| May 29, 2024 |
Exhibit 24.1 STERIS PLC POWER OF ATTORNEY FORM 10-K Each of the undersigned hereby makes, constitutes, and appoints Daniel A. Carestio, Michael J. Tokich, Karen L. Burton, and J. Adam Zangerle, and each of them, his or her true and lawful attorney, with full power of substitution, for and in his or her name, place, and stead, to affix, as attorney-in-fact, his or her signature in any and all capac |
|
| May 29, 2024 |
Exhibit 97.1 Compensation Clawback Policy Effective October 2, 2023 Purpose As required pursuant to the listing standards of the New York Stock Exchange (the “Stock Exchange”), Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 10D-1 under the Exchange Act, the Compensation and Organization Development Committee (the “Committee”) of the Board of Directors |
|
| May 29, 2024 |
United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-K United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38848 STERIS plc (Exact name of registrant as specified i |
|
| May 15, 2024 |
STERIS plc 70 Sir John Rogerson’s Quay Dublin 2 Ireland May 15, 2024 CORRESPONDENCE FILING VIA EDGAR U. |
|
| May 15, 2024 |
STERIS plc 70 Sir John Rogerson’s Quay Dublin 2 Ireland May 15, 2024 CORRESPONDENCE FILING VIA EDGAR U. |
|
| May 8, 2024 |
STERIS Announces Financial Results for Fiscal 2024 Fourth Quarter and Full Year Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2024 Fourth Quarter and Full Year • Total fiscal 2024 revenue increase 12% to $5.5 billion • Total fiscal 2024 U.S. GAAP earnings per diluted share of $3.81; adjusted earnings per diluted share increase to $8.83 • Targeted restructuring plan announced DUBLIN, IRELAND - (May 8, 2024) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) toda |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission File |
|
| April 11, 2024 |
Exhibit 99.1 STERIS to Sell Dental Segment to an affiliate of Peak Rock Capital • Transaction expected to close in STERIS’s first quarter of fiscal 2025 • Divestiture allows STERIS to focus on Customers within core markets • Proceeds primarily to be used to repay debt DUBLIN, IRELAND—(April 11, 2024)—STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the Company has entered in |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| April 9, 2024 |
STERIS plc 70 Sir John Rogerson’s Quay Dublin 2 Ireland April 9, 2024 CORRESPONDENCE FILING VIA EDGAR U. |
|
| April 9, 2024 |
STERIS plc 70 Sir John Rogerson’s Quay Dublin 2 Ireland April 9, 2024 CORRESPONDENCE FILING VIA EDGAR U. |
|
| February 13, 2024 |
STE / STERIS plc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01997-sterisplc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: STERIS PLC Title of Class of Securities: Common Stock CUSIP Number: G8473T100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule purs |
|
| February 9, 2024 |
STE / STERIS plc / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* STERIS PLC (Name of Issuer) Common Stock (Title of Class of Securities) G8473T100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 8, 2024 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated February 8, 2024 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for th |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| February 7, 2024 |
STERIS Announces Financial Results for Fiscal 2024 Third Quarter Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2024 Third Quarter • Third quarter revenue increases 15% as reported; 10% constant currency organic • As reported diluted earnings per share increased to $1.42; adjusted earnings per share increased to $2.22 • Fiscal 2024 outlook updated DUBLIN, IRELAND - (February 7, 2024) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announc |
|
| February 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission |
|
| January 30, 2024 |
STE / STERIS plc / WCM INVESTMENT MANAGEMENT, LLC - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* STERIS plc (Name of Issuer) Common (Title of Class of Securities) G8473T100 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| November 7, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2023 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated November 7, 2023 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for th |
|
| November 7, 2023 |
STERIS Announces Financial Results for Fiscal 2024 Second Quarter Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2024 Second Quarter • Second quarter revenue growth of 12% as reported and 8% constant currency organic • As reported diluted earnings per share increased to $1.16; adjusted earnings increased to $2.03 • Fiscal 2024 outlook maintained DUBLIN, IRELAND - (November 7, 2023) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission |
|
| November 7, 2023 |
Exhibit 10.1 Description of STERIS plc Non-Employee Director Compensation Program Summarized below is the Director compensation program for STERIS plc (“STERIS”) non-employee Directors for the term of office beginning July 27, 2023. Director retainer fees have been increased for the 2023-2024 term of office. An annual retainer of $323,000 is payable to each non-employee Director other than the Cha |
|
| August 8, 2023 |
ste6302023ex103 EXECUTION VERSION AMENDMENT NO. 2 THIS AMENDMENT NO. 2 (this “Agreement”), dated as of May 3, 2023, is entered into by STERIS PLC, a public limited company organized under the laws of Ireland (“STERIS plc”), STERIS LIMITED, a private limited company organized under the laws of England and Wales (“STERIS Limited”), STERIS CORPORATION, an Ohio corporation (“STERIS Corporation”), STER |
|
| August 8, 2023 |
AMENDED & RESTATED ASSET PURCHASE AGREEMENT BY AND BETWEEN STERIS CORPORATION (“PURCHASER”); BECTON, DICKINSON AND COMPANY (“SELLER”); AND STERIS PLC (“PARENT”), solely for the purposes set forth in Section 12. |
|
| August 8, 2023 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated August 8, 2023 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for the |
|
| August 8, 2023 |
EXECUTION VERSION AMENDMENT NO. 1 THIS AMENDMENT NO. 1 (this “Agreement”), dated as of May 3, 2023, is entered into by STERIS PLC, a public limited company organized under the laws of Ireland (“STERIS plc”), STERIS LIMITED, a private limited company organized under the laws of England and Wales (“STERIS Limited”), STERIS CORPORATION, an Ohio corporation (“STERIS Corporation”), STERIS IRISH FINCO U |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| August 8, 2023 |
ste6302023ex102 EXECUTION VERSION AMENDMENT NO. 1 THIS AMENDMENT NO. 1 (this “Agreement”), dated as of May 3, 2023, is entered into by STERIS PLC, a public limited company organized under the laws of Ireland (“STERIS plc”), STERIS LIMITED, a private limited company organized under the laws of England and Wales (“STERIS Limited”), STERIS CORPORATION, an Ohio corporation (“STERIS Corporation”), STER |
|
| August 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission Fi |
|
| August 1, 2023 |
STERIS Announces Financial Results for Fiscal 2024 First Quarter Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2024 First Quarter • First quarter revenue growth of 11% as reported and constant currency organic • As reported diluted earnings per share increased to $1.25; adjusted earnings increased to $2.00 • Fiscal 2024 outlook updated to reflect acquisition of BD surgical instrumentation assets DUBLIN, IRELAND - (August 1, 2023) - STERIS plc (NYSE |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| June 23, 2023 |
Securities and Exchange Commission Washington, D. C. 20549 FORM 11-K Securities and Exchange Commission Washington, D. C. 20549 FORM 11-K ý Annual Report Pursuant to Section 15(d) of The Securities Exchange Act of 1934 For the Twelve Month Period Ended December 31, 2022 OR o Transition Report Pursuant to Section 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38848 A. Full title of the plan and the address o |
|
| June 20, 2023 |
EX-2.1 Exhibit 2.1 ASSET PURCHASE AGREEMENT BY AND BETWEEN STERIS CORPORATION (“PURCHASER”); BECTON, DICKINSON AND COMPANY (“SELLER”); AND STERIS PLC (“PARENT”), solely for the purposes set forth in Section 12.21 Dated as of June 15, 2023 TABLE OF CONTENTS ARTICLE 1. THE TRANSACTION AGREEMENT 1 1.1 Purchased Assets 1 1.2 Excluded Assets 3 1.3 Excluded Liabilities 4 1.4 Non-Assignable Assets 5 1.5 |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| June 20, 2023 |
EX-99.1 Exhibit 99.1 STERIS Expands Healthcare Products Offering with Acquisition of Surgical Instrumentation Assets from Becton, Dickinson and Company for $540 million • A natural extension for STERIS in the operating room and sterile processing department • A primarily consumables product portfolio • Transaction expected to close by September 30, 2023 DUBLIN, IRELAND - (June 20, 2023) - STERIS p |
|
| June 7, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| June 7, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only as permitted by Rule 14a |
|
| May 31, 2023 |
EX-1.01 Exhibit 1.01 STERIS plc Conflict Minerals Report for the Reporting Period from January 1, 2022 to December 31, 2022 Introduction This Conflict Minerals Report is filed by STERIS plc (“STERIS”) for the reporting period from January 1, 2022 to December 31, 2022 (the “Reporting Period”) as Exhibit 1.01 to STERIS’s Form SD pursuant to the requirements of Rule 13p-1 of the Securities Exchange A |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT STERIS plc (Exact name of registrant as specified in its charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 70 Sir John Rogerson’s Quay, Dublin 2, Ireland D02 R296 (Address of princ |
|
| May 26, 2023 |
Exhibit 10.17 FORM OF STERIS PLC NONQUALIFIED STOCK OPTION AGREEMENT FOR EMPLOYEES – , This Agreement (“Agreement”) is between STERIS plc (“STERIS”) and (“Optionee”), with respect to the grant of a Nonqualified Stock Option by STERIS to Optionee pursuant to the STERIS plc 2006 Long-Term Equity Incentive Plan, as Amended and Restated Effective August 2, 2016, and as further amended from time to tim |
|
| May 26, 2023 |
Exhibit 21.1 SUBSIDIARIES OF STERIS PLC STERIS plc has no parent company. As of March 31, 2023, its direct and indirect subsidiaries were as follows: 1666 E Touhy LLC Illinois Accelera Technologies, LLC Minnesota Accutron, Inc. Arizona Albert Browne Limited England and Wales American Sterilizer Company Pennsylvania Bioster-Mottahedoon Egypt SAE Egypt Birkova Products, LLC Indiana Bizworth Gammarad |
|
| May 26, 2023 |
Exhibit 24.1 STERIS PLC POWER OF ATTORNEY FORM 10-K Each of the undersigned hereby makes, constitutes, and appoints Daniel A. Carestio, Michael J. Tokich, Karen L. Burton, and J. Adam Zangerle, and each of them, his or her true and lawful attorney, with full power of substitution, for and in his or her name, place, and stead, to affix, as attorney-in-fact, his or her signature in any and all capac |
|
| May 26, 2023 |
United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-K United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38848 STERIS plc (Exact name of registrant as specified i |
|
| May 26, 2023 |
Exhibit 10.16 FORM OF STERIS plc RESTRICTED STOCK AGREEMENT FOR EMPLOYEES - , This Agreement (“Agreement”) is between STERIS plc (“STERIS”) and < firstname> < lastname> (“Grantee”), with respect to the grant of shares of STERIS restricted stock to Grantee pursuant to the STERIS plc 2006 Long-Term Equity Incentive Plan, as Assumed, Amended and Restated Effective March 28, 2019, and as further amend |
|
| May 26, 2023 |
Exhibit 10.24 AMENDMENT NO. 2 TO STERIS PLC MANAGEMENT INCENTIVE COMPENSATION PLAN (As Assumed, Amended and Restated Effective March 28, 2019) WHEREAS, on March 28, 2019, the Redomiciliation of STERIS plc, a public limited company organized under the laws of England and Wales, from the United Kingdom to Ireland (the “Redomiciliation”) pursuant to a court-approved scheme of arrangement under Englis |
|
| May 10, 2023 |
STERIS Announces Financial Results for Fiscal 2023 Fourth Quarter and Full Year Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2023 Fourth Quarter and Full Year • Fourth quarter as reported revenue increased 14%; 16% constant currency organic revenue growth • Fourth quarter as reported earnings per share of $1.88; adjusted EPS of $2.30 • Fiscal 2024 Outlook provided DUBLIN, IRELAND - (May 10, 2023) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announc |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission File |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp |
|
| May 3, 2023 |
STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors EX-99.1 Exhibit 99.1 STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors DUBLIN, IRELAND – May 3, 2023 – STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. “We are pleased to welcome Dr. Alegria to our Board,” said Mohsen Sohi, Chairman of STERIS. “She brings over three decades of |
|
| February 10, 2023 |
STE / Steris PLC / WCM INVESTMENT MANAGEMENT, LLC - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* STERIS plc (Name of Issuer) Common (Title of Class of Securities) G8473T100 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 9, 2023 |
STE / Steris PLC / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01966-sterisplc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: STERIS plc Title of Class of Securities: Common Stock CUSIP Number: G8473T100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule purs |
|
| February 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission |
|
| February 8, 2023 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated February 8, 2023 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for th |
|
| February 8, 2023 |
STERIS Announces Financial Results for Fiscal 2023 Third Quarter Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2023 Third Quarter • As reported revenue increased 1%; 7% constant currency organic revenue growth • As reported earnings per share of $1.24; adjusted EPS of $2.02 • Updated outlook provided DUBLIN, IRELAND - (February 8, 2023) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 third |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| February 8, 2023 |
STE / Steris PLC / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* STERIS PLC (Name of Issuer) Common Stock (Title of Class of Securities) G8473T100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| November 9, 2022 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated November 9, 2022 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for th |
|
| November 9, 2022 |
Description of STERIS Non-Employee Director Compensation Program* EXHIBIT 10.4 Description of STERIS plc Non-Employee Director Compensation Program Summarized below is the Director compensation program for STERIS plc (?STERIS?) non-employee Directors for the term of office beginning July 28, 2022. Director retainer fees have been increased for the 2022-2023 term of office. An annual retainer of $315,000 is payable to each non-employee Director other than the Cha |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| November 9, 2022 |
STERIS Announces Financial Results for Fiscal 2023 Second Quarter Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2023 Second Quarter ? As reported revenue was flat; 7% constant currency organic revenue growth ? As reported loss per share of ($3.15); adjusted EPS of $1.99 ? As reported loss includes an impairment charge of $490.6 million related to the Dental segment DUBLIN, IRELAND - (November 9, 2022) - STERIS plc (NYSE: STE) (?STERIS? or the ?Compa |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission |
|
| August 8, 2022 |
Exhibit 10.3 DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT This Director and Officer Indemnification Agreement, dated as of , 20 (this ?Agreement?), is made by and between STERIS Corporation, an Ohio corporation (the ?Company?), and (?Indemnitee?). RECITALS: A. In recognition of the need for corporations to be able to induce capable and responsible persons to accept and continue in positions in c |
|
| August 8, 2022 |
Exhibit 10.2 DATED STERIS plc and [Insert Name] DEED OF INDEMNIFICATION MATHESON 70 Sir John Rogerson?s Quay Dublin 2 Ireland TEL: + 353 1 232 2000 FAX: +353 1 232 3333 53466063.3 46477852.1 CONTENTS Page No 1 Interpretation ............................................................................................................................. 1 2 Agreement to Serve .......................... |
|
| August 8, 2022 |
Exhibit 10.1 DATED STERIS plc and [Insert Name] DEED OF INDEMNIFICATION MATHESON 70 Sir John Rogerson?s Quay Dublin 2 Ireland TEL: + 353 1 232 2000 FAX: +353 1 232 3333 56258095.1 46477852.1 CONTENTS Page No 1 Interpretation ............................................................................................................................. 1 2 Agreement to Serve .......................... |
|
| August 8, 2022 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated August 8, 2022 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for the |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| August 2, 2022 |
STERIS Announces Financial Results for Fiscal 2023 First Quarter Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2023 First Quarter • First quarter revenue increases 19% as reported; 6% constant currency organic • As reported EPS of $1.10; adjusted EPS of $1.90 • Updated outlook provided DUBLIN, IRELAND - (August 2, 2022) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 first quarter ended Jun |
|
| August 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission Fi |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| June 24, 2022 |
Securities and Exchange Commission Washington, D. C. 20549 FORM 11-K Securities and Exchange Commission Washington, D. C. 20549 FORM 11-K ? Annual Report Pursuant to Section 15(d) of The Securities Exchange Act of 1934 For the Twelve Month Period Ended December 31, 2021 OR o Transition Report Pursuant to Section 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38848 A. Full title of the plan and the address o |
|
| June 7, 2022 |
DEFA14A 1 d301219ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| June 7, 2022 |
DEF 14A 1 d290847ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| May 31, 2022 |
SD 1 d350242dsd.htm FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT STERIS plc (Exact name of registrant as specified in its charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 70 Sir John Rogerson’s Quay, Dublin 2, Ireland DE21 6LY (Addr |
|
| May 31, 2022 |
Exhibit 21.1 SUBSIDIARIES OF STERIS PLC STERIS plc has no parent company. As of March 31, 2022, its direct and indirect subsidiaries(1) were as follows: Accelera Technologies LLC Minnesota Accutron, Inc. Arizona Albert Browne Limited England & Wales American Sterilizer Company Pennsylvania BHT Hygienetechnik Holding GmbH Germany Bioster Mottahedoon Egypt SAE Egypt Birkova Products Indiana Bizworth |
|
| May 31, 2022 |
Exhibit 1.01 STERIS plc Conflict Minerals Report for the Reporting Period from January 1, 2021 to December 31, 2021 Introduction This Conflict Minerals Report is filed by STERIS plc (?STERIS?) for the reporting period from January 1, 2021 to December 31, 2021 (the ?Reporting Period?) as Exhibit 1.01 to STERIS?s Form SD pursuant to the requirements of Rule 13p-1 of the Securities Exchange Act of 19 |
|
| May 31, 2022 |
EXECUTION VERSIONEXHIBIT 10.40 AMENDMENT NO. 1 THIS AMENDMENT NO. 1 (this ?Agreement?), dated as of January 1, 2022, is entered into by JPMORGAN CHASE BANK, N.A., as administrative agent (in such capacity, the ?Administrative Agent?). RECITALS WHEREAS, the STERIS PLC, a public limited company organized under the laws of Ireland (?STERIS plc?), STERIS LIMITED, a private limited company organized un |
|
| May 31, 2022 |
United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-K United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38848 STERIS plc (Exact name of registrant as specified i |
|
| May 31, 2022 |
Exhibit 24.1 STERIS PLC POWER OF ATTORNEY FORM 10-K Each of the undersigned hereby makes, constitutes, and appoints Daniel A. Carestio, Michael J. Tokich, Karen L. Burton, J. Adam Zangerle, and Ronald E. Snyder, and each of them, his or her true and lawful attorney, with full power of substitution, for and in his or her name, place, and stead, to affix, as attorney-in-fact, his or her signature in |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission File |
|
| May 12, 2022 |
STERIS Announces Financial Results for Fiscal 2022 Fourth Quarter and Full Year Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2022 Fourth Quarter and Full Year ? Fourth quarter revenue increases 39% as reported; 11% constant currency organic ? As reported EPS of $0.52; adjusted EPS of $2.04 ? Company provides FY23 Outlook DUBLIN, IRELAND - (May 11, 2022) - STERIS plc (NYSE: STE) (?STERIS? or the ?Company?) today announced financial results for its fiscal 2022 fou |
|
| February 10, 2022 |
STE / Steris PLC / WCM INVESTMENT MANAGEMENT, LLC - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* STERIS plc (Name of Issuer) Common (Title of Class of Securities) G8473T100 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 10, 2022 |
STE / Steris PLC / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: STERIS plc Title of Class of Securities: Common Stock CUSIP Number: G8473T100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d |
|
| February 9, 2022 |
Exhibit 22.1 List of Guarantor Subsidiaries with respect to the 2.700% Senior Notes due 2031 and 3.750% Senior Notes due 2051 issued by STERIS Irish FinCo Unlimited Company Senior Notes Issued Under Issuer Guarantors 2021 Indenture STERIS Irish FinCo Unlimited Company STERIS plc, STERIS Corporation, STERIS Limited |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number |
|
| February 9, 2022 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated February 9, 2022 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for th |
|
| February 8, 2022 |
STERIS Announces Financial Results for Fiscal 2022 Third Quarter Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2022 Third Quarter ? Third quarter revenue increases 49% as reported; 9% constant currency organic ? As reported EPS of $1.42; adjusted EPS of $2.12 ? Outlook for FY22 raised DUBLIN, IRELAND - (February 8, 2022) - STERIS plc (NYSE: STE) (?STERIS? or the ?Company?) today announced financial results for its fiscal 2022 third quarter ended De |
|
| February 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2022 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission F |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission |
|
| November 8, 2021 |
EXHIBIT 10.3 TRANSITION AGREEMENT THIS TRANSITION AGREEMENT ("Agreement") is made as of the 29th day of January 2021 and will take effect on the 31st day of July, 2021 (the "Effective Date") by and between STERIS Corporation, an Ohio corporation ("Employer"), and STERIS plc, an Irish public limited company ("Parent", and together with the Employer, "Company"), and Walter M Rosebrough, Jr. ("Execut |
|
| November 8, 2021 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated November 8, 2021 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for th |
|
| November 8, 2021 |
Exhibit 22.1 List of Guarantor Subsidiaries with respect to the 2.700% Senior Notes due 2031 and 3.750% Senior Notes due 2051 issued by STERIS Irish FinCo Unlimited Company Senior Notes Issued Under Issuer Guarantors 2021 Indenture STERIS Irish FinCo Unlimited Company STERIS plc, STERIS Corporation, STERIS Limited |
|
| November 8, 2021 |
Description of STERIS Non-Employee Director Compensation Program Exhibit 10.1 Description of STERIS Non-Employee Director Compensation Program The Director compensation program for STERIS plc (?STERIS?) non-employee Directors for the term of office beginning July 29, 2021 is summarized below. An annual retainer of $300,000 is payable for the 2021-2022 term of office to each non- employee Director other than the Chairman of the Board. An annual retainer of $450, |
|
| November 8, 2021 |
EXHIBIT 10.2 AMENDMENT NO. 1 TO STERIS PLC 2006 LONG-TERM EQUITY INCENTIVE PLAN (AS ASSUMED, AMENDED AND RESTATED EFFECTIVE MARCH 28, 2019) (?PLAN?) WHEREAS, STERIS plc (the ?Company?) assumed, amended and restated the Plan effective March 28, 2019; and WHEREAS, the Compensation and Organization Development Committee of the Board of Directors of the Company authorized this Amendment of the Plan on |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| November 2, 2021 |
STERIS Announces Financial Results for Fiscal 2022 Second Quarter Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2022 Second Quarter ? Second quarter revenue increases 58% as reported; 12% constant currency organic ? As reported EPS of $0.69; adjusted EPS of $1.99 ? Company reiterates fiscal 2022 outlook DUBLIN, IRELAND - (November 2, 2021) - STERIS plc (NYSE: STE) (?STERIS? or the ?Company?) today announced financial results for its fiscal 2022 seco |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission |
|
| August 9, 2021 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated August 9, 2021 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for the |
|
| August 9, 2021 |
STERIS Announces Financial Results for Fiscal 2022 First Quarter Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2022 First Quarter ? First quarter revenue increases 45% as reported; 21% constant currency organic ? Cantel Medical integration on track ? Company increases outlook and raises quarterly dividend DUBLIN, IRELAND - (August 9, 2021) - STERIS plc (NYSE: STE) (?STERIS? or the ?Company?) today announced financial results for its fiscal 2022 fir |
|
| August 9, 2021 |
Exhibit 22.1 List of Guarantor Subsidiaries with respect to the 2.700% Senior Notes due 2031 and 3.750% Senior Notes due 2051 issued by STERIS Irish FinCo Unlimited Company Senior Notes Issued Under Issuer Guarantors 2021 Indenture STERIS Irish FinCo Unlimited Company STERIS plc, STERIS Corporation, STERIS Limited |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission Fi |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| August 2, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| June 15, 2021 |
Securities and Exchange Commission Washington, D. C. 20549 FORM 11-K Securities and Exchange Commission Washington, D. C. 20549 FORM 11-K ? Annual Report Pursuant to Section 15(d) of The Securities Exchange Act of 1934 For the Twelve Month Period Ended December 31, 2020 OR o Transition Report Pursuant to Section 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38848 A. Full title of the plan and the address o |
|
| June 8, 2021 |
Exhibit 4.1 CANTEL MEDICAL LLC AND STERIS PLC AND WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE June 2, 2021 3.25% Convertible Senior Notes due 2025 FIRST SUPPLEMENTAL INDENTURE, dated as of June 2, 2021 (this ?First Supplemental Indenture?), among CANTEL MEDICAL LLC, a Delaware limited liability company (formerly known as Cantel Medical Corp., the ?Company?), STE |
|
| June 8, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL DATA Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL DATA The following unaudited condensed combined pro forma financial data (?pro forma financial data?) combines the historical consolidated financial positions and results of operations of STERIS plc (?STERIS?) and Cantel Medical Corp. (?Cantel?) as an acquisition by STERIS of Cantel. The transaction was announced on January 12, 2021 and |
|
| June 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em |
|
| June 7, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| June 2, 2021 |
Exhibit 4.6 OMNIBUS AMENDMENT TO CANTEL MEDICAL CORP. 2016 EQUITY INCENTIVE PLAN AND CANTEL MEDICAL CORP. 2020 EQUITY INCENTIVE PLAN STERIS plc, a public limited company incorporated under the laws of Ireland (the ?Company?), hereby adopts this Omnibus Amendment (this ?Amendment?) to Cantel Medical Corp. 2016 Equity Incentive Plan (the ?2016 Plan?) and Cantel Medical Corp. 2020 Equity Incentive Pl |
|
| June 2, 2021 |
As filed with the Securities and Exchange Commission on June 2, 2021 As filed with the Securities and Exchange Commission on June 2, 2021 Registration No. |
|
| June 2, 2021 |
EXHIBIT 24.1 STERIS PLC REGISTRATION STATEMENT ON FORM S-8 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned officers and directors of STERIS plc, a public limited company organized under the laws or Ireland (the ?Registrant?), hereby constitutes and appoints Dr. Moshen M. Sohi, Walter M Rosebrough, Jr., Daniel A. Carestio, Michael J. Tokich, J. Adam Zangerle and K |
|
| June 1, 2021 |
Consent of Centerview Partners LLC Exhibit 23.7 Consent of Centerview Partners LLC The Board of Directors Cantel Medical Corp. 150 Clove Road Little Falls, NJ 07424 The Board of Directors: We hereby consent to the inclusion of our opinion letter, dated January 12, 2021, to the Board of Directors of Cantel Medical Corp. (“Cantel”) as Annex B to, and reference to such opinion letter under the headings “Summary—Opinion of Cantel’s Fin |
|
| June 1, 2021 |
As filed with the Securities and Exchange Commission on June 1, 2021 As filed with the Securities and Exchange Commission on June 1, 2021 Registration No. |
|
| June 1, 2021 |
LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the Registration Statement on Form S-4 filed pursuant to General Instruction K to Form S-4 and Rule 462(b) of the Securities Act of 1933 of our review reports dated August 7, 2020, November 6, 2020 and February 9, 2021 relating to th |
|
| June 1, 2021 |
Exhibit 1.01 STERIS plc Conflict Minerals Report for the Reporting Period from January 1, 2020 to December 31, 2020 Introduction This Conflict Minerals Report is filed by STERIS plc (?STERIS?) for the reporting period from January 1, 2020 to December 31, 2020 (the ?Reporting Period?) as Exhibit 1.01 to STERIS?s Form SD pursuant to the requirements of Rule 13p-1 of the Securities Exchange Act of 19 |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT STERIS plc (Exact name of registrant as specified in its charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 70 Sir John Rogerson?s Quay, Dublin 2, Ireland DE21 6LY (Address of principal executive o |
|
| May 28, 2021 |
Exhibit 22.1 List of Guarantor Subsidiaries with respect to the 2.700% Notes due 2031 and 3.750% Notes due 2051 issued by STERIS Irish Finco Unlimited Company Senior Notes Issued Under Issuer Guarantors 2021 Indenture STERIS Irish Finco Unlimited Company STERIS plc, STERIS Corporation, STERIS Limited |
|
| May 28, 2021 |
Exhibit 18.1 May 28, 2021 The Board of Directors of STERIS plc 70 Sir John Rogerson?s Quay Dublin 2 Ireland Ladies and Gentlemen: Note 1 of the Notes to the consolidated financial statements of STERIS plc and subsidiaries included in its Annual Report on Form 10-K for the year ended March 31, 2021 describes a change in the method of accounting for inventory valuation from the last-in, first-out (L |
|
| May 28, 2021 |
Exhibit 24.1 STERIS PLC POWER OF ATTORNEY FORM 10-K Each of the undersigned hereby makes, constitutes, and appoints Walter M Rosebrough, Jr., Daniel A. Carestio, Michael J. Tokich, Karen L. Burton, J. Adam Zangerle, Ronald E. Snyder, Julia Kipnis, and each of them, his or her true and lawful attorney, with full power of substitution, for and in his or her name, place, and stead, to affix, as attor |
|
| May 28, 2021 |
Exhibit 4.5 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES AND EXCHANGE ACT OF 1934 As of the date hereof, STERIS plc, a public limited company incorporated under the laws of Ireland, and its subsidiaries have three classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: ordinary shares of STERIS plc and |
|
| May 28, 2021 |
United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-K United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38848 STERIS plc (Exact name of registrant as specified i |
|
| May 28, 2021 |
Exhibit 21.1 SUBSIDIARIES OF STERIS PLC STERIS plc has no parent company. As of March 31, 2021, its direct and indirect subsidiaries(1) were as follows: Albert Browne Limited England & Wales American Sterilizer Company Pennsylvania Bioster Mottahedoon Egypt SAE Egypt Birkova Products Indiana Bizworth Gammarad Sdn Bhd Malaysia Black Diamond Video, Inc. California CLBV Limited England & Wales Contro |
|
| May 19, 2021 |
STERIS Announces Financial Results for Fiscal 2021 Fourth Quarter and Full Year Filed by STERIS plc Commission File No. 001-38848 Pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Cantel Medical Corp. Commission File No.: 001-31337 Date 05/18/2021 STERIS Announces Financial Results for Fiscal 2021 Fourth Quarter and Full Year ? Fourth quarter revenue increases 6% as reported; full year increases 3% as reported ? Full year earnings per diluted |
|
| May 19, 2021 |
Filed by STERIS plc Commission File No.: 001-38848 Pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Cantel Medical Corp. Commission File No.: 001-31337 Date 05/19/2021 Corrected Transcript Total Pages: 15 19-May-2021 1-877-FACTSET www.callstreet.com Copyright ? 2001-2021 FactSet CallStreet, LLC STERIS Plc (Ireland) (STE)Q4 2021 Earnings Call STERIS Plc (Ireland) ( |
|
| May 18, 2021 |
STERIS Announces Financial Results for Fiscal 2021 Fourth Quarter and Full Year Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2021 Fourth Quarter and Full Year ? Fourth quarter revenue increases 6% as reported; full year increases 3% as reported ? Full year earnings per diluted share of $4.63 on a U.S. GAAP basis and $6.17 on an adjusted basis on effective tax rates of 23.3% and 20.7%, respectively ? Company provides outlook for fiscal 2022 including Cantel Medic |
|
| May 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission File |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp |
|
| May 11, 2021 |
Exhibit 99.1 STERIS Announces Changes to Board of Directors ? David B. Lewis to retire at the Company?s 2021 Annual Meeting of Shareholders ? Company appoints Paul E. Martin to Board DUBLIN, IRELAND?(May 11, 2021)?STERIS plc (NYSE: STE) (?STERIS? or the ?Company?) today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for electi |
|
| May 3, 2021 |
Filed by STERIS plc Commission File No.: 001-38848 Pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Cantel Medical Corp. Commission File No.: 001-31337 Date 05/03/2021 Dear Cantel and STERIS Associates: Over the past few months, we have achieved a number of key objectives in our quest to complete the combination of STERIS and Cantel. We are excited to share that a |
|
| April 27, 2021 |
STERIS Announces Preliminary Financial Results for Fiscal 2021 Exhibit 99.1 STERIS Announces Preliminary Financial Results for Fiscal 2021 ? Company expects to close the Cantel Medical acquisition by June 2, 2021, pending shareholder vote DUBLIN, IRELAND - (April 27, 2021) - STERIS plc (NYSE: STE) (?STERIS? or the ?Company?) today announced preliminary financial results for its fiscal 2021 year ending March 31, 2021. The Company expects to report that revenue |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| April 27, 2021 |
STERIS Announces Preliminary Financial Results for Fiscal 2021 Exhibit 99.1 STERIS Announces Preliminary Financial Results for Fiscal 2021 ? Company expects to close the Cantel Medical acquisition by June 2, 2021, pending shareholder vote DUBLIN, IRELAND - (April 27, 2021) - STERIS plc (NYSE: STE) (?STERIS? or the ?Company?) today announced preliminary financial results for its fiscal 2021 year ending March 31, 2021. The Company expects to report that revenue |
|
| April 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| April 12, 2021 |
Filed by STERIS plc Commission File No.: 001-38848 Pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Cantel Medical Corp. Commission File No.: 001-31337 Date: 04/12/2021 April 12, 2021 Dear Cantel Employees: Since we last reached out to you to share the news of our CEO succession plan in February, we have been very busy behind the scenes working to successfully clo |
|
| April 1, 2021 |
Exhibit 4.2 Execution Version STERIS IRISH FINCO UNLIMITED COMPANY AND THE GUARANTORS PARTY HERETO AND U.S. BANK NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of April 1, 2021 $675,000,000 of 2.700% Senior Notes due 2031 $675,000,000 of 3.750% Senior Notes due 2051 THIS FIRST SUPPLEMENTAL INDENTURE (the ?First Supplemental Indenture?) is dated as of April 1, 2021 among STE |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 STERIS plc STERIS Irish FinCo Unlimited Company Ireland Ireland 98-1455064 98-1271422 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiz |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| April 1, 2021 |
LETTER TO STOCKHOLDERS OF CANTEL TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-253799 LETTER TO STOCKHOLDERS OF CANTEL Dear Stockholders: On January 12, 2021, Cantel Medical Corp., which is referred to as Cantel, and STERIS plc, Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC, which are referred to as STERIS, US Holdco and Crystal Merger Sub, respectively, entered into an Agreement and Plan of |
|
| April 1, 2021 |
Exhibit 4.1 STERIS IRISH FINCO UNLIMITED COMPANY as Issuer AND THE GUARANTORS PARTY HERETO AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of April 1, 2021 DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.01. Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 8 Section 2.01. Designation and Terms |
|
| April 1, 2021 |
Exhibit 1.1 Execution Version $1,350,000,000 STERIS Irish FinCo Unlimited Company 2.700% Senior Notes due 2031 3.750% Senior Notes due 2051 Underwriting Agreement March 24, 2021 J.P. Morgan Securities LLC BofA Securities, Inc. Citigroup Global Markets Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York |
|
| April 1, 2021 |
Consent of Jones Day (included in Exhibit 5.3 hereof). Exhibit 5.3 AUTHORISED AND REGULATED BY THE SOLICITORS REGULATION AUTHORITY SRA NO. 223597 21 TUDOR STREET ? LONDON EC4Y ODJ ? DX 67 LONDON/CHANCERY TELEPHONE: +44.020.7039.5959 ? FACSIMILE: +44.020.7039.5999 Date 1 April 2021 STERIS plc STERIS Irish FinCo Unlimited Company STERIS Corporation STERIS Limited c/o STERIS plc 70 Sir John Rogerson?s Quay Dublin 2 Ireland D02 R296 Re: $675,000,000 of 2. |
|
| March 30, 2021 |
CORRESP 1 filename1.htm STERIS plc 70 Sir John Rogerson’s Quay Dublin 2 Ireland D02 R296 Tel: +351 1 232 2000 March 30, 2021 VIA EDGAR CORRESPONDENCE Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Dillon Hagius, Attorney Advisor Division of Corporation Finance Office of Life Sciences Re: STERIS plc Amendment No. 1 to Registration |
|
| March 30, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 29, 2021 Registration No. |
|
| March 30, 2021 |
Consent of Centerview Partners LLC Exhibit 23.7 Consent of Centerview Partners LLC The Board of Directors Cantel Medical Corp. 150 Clove Road Little Falls, NJ 07424 The Board of Directors: We hereby consent to the inclusion of our opinion letter, dated January 12, 2021, to the Board of Directors of Cantel Medical Corp. (“Cantel”) as Annex B to, and reference to such opinion letter under the headings “Summary—Opinion of Cantel’s Fin |
|
| March 30, 2021 |
LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION EX-15.1 5 nt10018921x2ex15-1.htm EXHIBIT 15.1 Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in Amendment No. 1 to the Registration Statement (Form S-4 No. 333-253799) and related proxy statement/prospectus of STERIS plc for the registration of 14,287,997 shares of its common stock |
|
| March 26, 2021 |
Form 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254608 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Maximum Offering Price per Unit Maximum Aggregate Offering Price Amount of Registration Fee(1) 2.700% Senior Notes due 2031 $675,000,000 99.897% $674,304,750 $73,566.65 Guarantees of 2.700% Senior Notes |
|
| March 24, 2021 |
STERIS IRISH FINCO UNLIMITED COMPANY Pricing Term Sheet Filed Pursuant to Rule 433 Registration Statement No. 333-254608 Pricing Term Sheet STERIS IRISH FINCO UNLIMITED COMPANY Pricing Term Sheet The information in this pricing term should be read together with (i) the preliminary prospectus supplement, dated March 24, 2021, as filed with the Securities and Exchange Commission (the ?SEC?) pursuant to Rule 424(b) under the Securities Act of 1933, as ame |
|
| March 24, 2021 |
STERIS Investor Relations 5960 Heisley Road Mentor, Ohio 44060 Telephone Number: +1 440 354 2600 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254608 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitt |
|
| March 23, 2021 |
Power of Attorney of Directors and Officers of STERIS plc Exhibit 24.1 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that each of the undersigned directors and officers of STERIS plc, an Irish public limited company, does hereby constitute and appoint Walter M Rosebrough, Jr., Michael J. Tokich and J. Adam Zangerle, and each of them acting individually, as the true and lawful attorney-in-fact or attorneys-in-fact for each of the undersigned, with full po |
|
| March 23, 2021 |
Exhibit 10.5 EXECUTION VERSION STERIS CORPORATION FIRST AMENDMENT Dated as of March 19, 2021 to AMENDED AND RESTATED NOTE PURCHASE AGREEMENT Dated as of March 5, 2019 Re: $125,000,000 3.45% SENIOR NOTES, SERIES A-1, DUE MAY 14, 2025 $125,000,000 3.55% SENIOR NOTES, SERIES A-2, DUE MAY 14, 2027 $100,000,000 3.70% SENIOR NOTES, SERIES A-3, DUE MAY 14, 2030 FIRST AMENDMENT TO THE AMENDED AND RESTATED |
|
| March 23, 2021 |
Exhibit 10.4 EXECUTION VERSION STERIS CORPORATION FIRST AMENDMENT Dated as of March 19, 2021 to AMENDED AND RESTATED NOTE PURCHASE AGREEMENT Dated as of March 5, 2019 RE: $47,500,000 3.20% SENIOR NOTES, SERIES A-1A, DUE DECEMBER 4, 2022 $47,500,000 3.20% SENIOR NOTES, SERIES A-1B, DUE DECEMBER 4, 2022 $40,000,000 3.35% SENIOR NOTES, SERIES A-2A, DUE DECEMBER 4, 2024 $40,000,000 3.35% SENIOR NOTES, |
|
| March 23, 2021 |
Exhibit 10.1 Execution Version $750,000,000 TERM LOAN AGREEMENT Dated as of March 19, 2021 among STERIS PLC, as a Borrower, STERIS LIMITED, as a Borrower, STERIS CORPORATION, as a Borrower, STERIS IRISH FINCO UNLIMITED COMPANY, as a Borrower, The Guarantors Party Hereto, VARIOUS FINANCIAL INSTITUTIONS, as Lenders, and JPMORGAN CHASE BANK, N.A., as Administrative Agent BOFA SECURITIES, INC., CITIBA |
|
| March 23, 2021 |
Exhibit 3.5 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF STERIS CORPORATION ARTICLE I The name of the corporation (which is hereinafter referred to as the ?Corporation?) is: STERIS Corporation. ARTICLE II The place in Ohio where its principal office is to be located is the City of Mentor in Lake County. ARTICLE III The purpose of the Corporation shall be to engage in any lawful act or activit |
|
| March 23, 2021 |
Exhibit 5.3 Date 23 March 2021 STERIS plc STERIS Irish FinCo Unlimited Company STERIS Corporation STERIS Limited c/o STERIS plc 70 Sir John Rogerson?s Quay Dublin 2 Ireland D02 R296 Re: Registration Statement on Form S-3 filed by, amongst others, STERIS plc (a public limited company incorporated in Ireland, the ?Parent?), STERIS Irish FinCo Unlimited Company (a public unlimited company incorporate |
|
| March 23, 2021 |
Articles of Association of STERIS Limited Exhibit 3.8 STERIS LIMITED ARTICLES OF ASSOCIATION TABLE OF CONTENTS Page PRELIMINARY 1 1. DEFINITIONS 1 2. EXCLUSION OF MODEL ARTICLES 5 CAPITAL 5 3. LIABILITY OF MEMBERS 5 4. SHARE CAPITAL 5 5. ORDINARY SHARES 5 6. PREFERENCE SHARES 6 7. SECTION 551 AUTHORITY 6 8. SECTION 561 DISAPPLICATION 6 9. ALLOTMENT AFTER EXPIRY 7 10. DEFINITIONS FOR ARTICLES 5, 8 AND 9 7 11. ALLOTMENT POWERS?SECTION 551 A |
|
| March 23, 2021 |
Exhibit 10.6 EXECUTION VERSION STERIS LIMITED (formerly known as STERIS plc) FIRST AMENDMENT Dated as of March 19, 2021 to AMENDED AND RESTATED NOTE PURCHASE AGREEMENT Dated as of March 5, 2019 RE: $50,000,000 3.93% SENIOR NOTES, SERIES A-1, DUE FEBRUARY 27, 2027 ?60,000,000 1.86% SENIOR NOTES, SERIES A-2, DUE FEBRUARY 27, 2027 $45,000,000 4.03% SENIOR NOTES, SERIES A-3, DUE FEBRUARY 27, 2029 ?20, |
|
| March 23, 2021 |
Power of Attorney of Directors of STERIS Irish FinCo Unlimited Exhibit 24.2 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that each of the undersigned directors of STERIS Irish FinCo Unlimited Company, a public unlimited company incorporated under the laws of Ireland, does hereby constitute and appoint Walter M Rosebrough, Jr., Michael J. Tokich and J. Adam Zangerle, and each of them acting individually, as the true and lawful attorney-in-fact or attorneys-in |
|
| March 23, 2021 |
Exhibit 3.4 ARTICLES OF ASSOCIATION OF STERIS IRISH FINCO UNLIMITED COMPANY 1 Interpretation 1.1 In this Constitution: ?Act? means the Companies Act 2014 and every statutory modification or re-enactment thereof for the time being in force; ?Company? means Steris Irish FinCo Unlimited Company; ?Constitution? has the meaning set out in regulation 1.2; ?director? means a director of the Company and t |
|
| March 23, 2021 |
Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the Registration Statement (Form S-3) and related Prospectus of STERIS plc for the registration of debt securities, guarantees of debt securities, ordinary shares, preferred shares, warrants, and units of our reports dated August 7, |
|
| March 23, 2021 |
Exhibit 10.2 Execution Version $550,000,000 TERM LOAN AGREEMENT Dated as of March 19, 2021 among STERIS PLC, as a Borrower, STERIS LIMITED, as a Borrower, STERIS CORPORATION, as a Borrower, STERIS IRISH FINCO UNLIMITED COMPANY, as a Borrower, The Guarantors Party Hereto, VARIOUS FINANCIAL INSTITUTIONS, as Lenders, and JPMORGAN CHASE BANK, N.A., as Administrative Agent BOFA SECURITIES, INC., CITIBA |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| March 23, 2021 |
Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 31-0841368 I.R.S. Employer Identif |
|
| March 23, 2021 |
Exhibit 3.3 MEMORANDUM OF ASSOCIATION OF STERIS IRISH FINCO UNLIMITED COMPANY 1 The name of the company is Steris Irish FinCo Unlimited Company (the ?Company?). 2 The Company is a public unlimited company having a share capital registered under Part 19 of the Companies Act 2014. 3 The objects for which the Company is established are: 3.1 To provide financing for STERIS Group activities. 3.2 To car |
|
| March 23, 2021 |
Form of STERIS plc Debt Securities Indenture Exhibit 4.1 STERIS PLC as Issuer AND THE GUARANTORS PARTY HERETO AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of , 20 DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.01. Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 8 Section 2.01. Designation and Terms of Securities 8 Section 2.02. Form |
|
| March 23, 2021 |
Exhibit 10.3 Execution Version $1,250,000,000 CREDIT AGREEMENT Dated as of March 19, 2021 among STERIS PLC, as a Borrower, STERIS LIMITED, as a Borrower, STERIS CORPORATION, as a Borrower, STERIS IRISH FINCO UNLIMITED COMPANY, as a Borrower, The Guarantors Party Hereto, VARIOUS FINANCIAL INSTITUTIONS, as Lenders, and JPMORGAN CHASE BANK, N.A., as Administrative Agent BOFA SECURITIES, INC., CITIBAN |
|
| March 23, 2021 |
Exhibit 3.2 Number: 570385 Certificate of Incorporation Public unlimited company with a share capital I hereby certify that STERIS IRISH FINCO formerly registered as ULC - Private Unlimited Company has this day been re-registered under the Companies Act 2014 as Public unlimited company with a share capital Given under my hand at Dublin, this Thursday 18 March 2021 for Registrar of Companies Signed |
|
| March 23, 2021 |
Exhibit 3.7 File Copy CERTIFICATE OF INCORPORATION OF A PRIVATE LIMITED COMPANY Company Number 9257343 The Registrar of Companies for England and Wales, hereby certifies that SOLAR NEW HOLDCO LIMITED is this day incorporated under the Companies Act 2006 as a private company, that the company is limited by shares, and the situation of its registered office is in England and Wales Given at Companies |
|
| March 23, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on March 23, 2021 Registration No. |
|
| March 23, 2021 |
Power of Attorney of Directors of STERIS Limited EX-24.4 21 d124684dex244.htm EX-24.4 Exhibit 24.4 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that each of the undersigned directors of STERIS Limited, a private limited company incorporated under the laws of England and Wales, does hereby constitute and appoint Walter M Rosebrough, Jr., Michael J. Tokich and J. Adam Zangerle, and each of them acting individually, as the true and lawful attorney |
|
| March 23, 2021 |
Power of Attorney of Directors and Officers of STERIS Corporation Exhibit 24.3 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that each of the undersigned directors and officers of STERIS Corporation, an Ohio corporation, does hereby constitute and appoint Walter M Rosebrough, Jr., Michael J. Tokich and J. Adam Zangerle, and each of them acting individually, as the true and lawful attorney-in-fact or attorneys-in-fact for each of the undersigned, with full power |
|
| March 23, 2021 |
Form of STERIS Irish FinCo Unlimited Company Debt Securities Indenture Exhibit 4.2 STERIS IRISH FINCO UNLIMITED COMPANY as Issuer AND THE GUARANTORS PARTY HERETO AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of , 20 DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.01. Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 8 Section 2.01. Designation and Terms of Secur |
|
| March 23, 2021 |
Amended and Restated Code of Regulations of STERIS Corporation Exhibit 3.6 AMENDED AND RESTATED CODE OF REGULATIONS OF STERIS CORPORATION ARTICLE I MEETINGS OF SHAREHOLDERS Section 1. Place of Meeting. Meetings of the shareholders may be held either within or without the State of Ohio. Section 2. Annual Meeting. The annual meeting of the shareholders, whereat the shareholders shall elect a Board of Directors, and transact such other business as may properly b |
|
| March 23, 2021 |
Exhibit 25.2 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 31-0841368 I.R.S. Employer Identif |
|
| March 2, 2021 |
Consent of Centerview Partners LLC Exhibit 23.7 Consent of Centerview Partners LLC The Board of Directors Cantel Medical Corp. 150 Clove Road Little Falls, NJ 07424 The Board of Directors: We hereby consent to the inclusion of our opinion letter, dated January 12, 2021, to the Board of Directors of Cantel Medical Corp. (“Cantel”) as Annex B to, and reference to such opinion letter under the headings “Summary—Opinion of Cantel’s Fin |
|
| March 2, 2021 |
LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the Registration Statement (Form S-4) and related proxy statement/prospectus of STERIS plc for the registration of 14,287,997 shares of its common stock of our reports dated August 7, 2020, November 6, 2020 and February 9, 2021 relat |
|
| March 2, 2021 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that each of the undersigned directors and officers of STERIS plc, an Irish public limited company (the ?Registrant?), does hereby constitute and appoint Walter M Rosebrough, Jr., Michael J. Tokich and J. Adam Zangerle, and each of them acting individually, as the true and lawful attorney-in-fact or attorneys-in-fact for each of the unders |
|
| March 2, 2021 |
Exhibit 99.1 |
|
| March 2, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 2, 2021 Registration No. |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: STERIS plc Title of Class of Securities: Common Stock CUSIP Number: G8473T100 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d |
|
| February 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission |
|
| February 9, 2021 |
EXHIBIT 10.5 GUARANTY SUPPLEMENT December 17, 2020 To the Holders of the Series A-1, A-2 and A-3, (each, as hereinafter defined) of STERIS Corporation (the “Company”) Ladies and Gentlemen: WHEREAS, in order to refinance certain debt and for general corporate purposes, the Company entered into that certain Amended and Restated Note Purchase Agreement, dated as of March 5, 2019 (as amended, amended |
|
| February 9, 2021 |
EXHIBIT 10.4 GUARANTY SUPPLEMENT December 17, 2020 To the Holders of the Series A-1A, A-1B, A-2A, A-2B, A-3A and A-3B Notes, (each, as hereinafter defined) of STERIS Corporation (the “Company”) Ladies and Gentlemen: WHEREAS, in order to refinance certain debt and for general corporate purposes, the Company entered into that certain Amended and Restated Note Purchase Agreement, dated as of March 5, |
|
| February 9, 2021 |
Exhibit 99.1 EXPLANATORY NOTE STERIS plc (the "Company") is filing this exhibit to reflect changes to the presentation of the Company’s financial information as set forth in the Company's Annual Report on Form 10-K for the year ended March 31, 2020 (the "Fiscal 2020 Form 10-K"), as filed with the Securities and Exchange Commission ("SEC") on May 29, 2020, in order to give effect to a change in seg |
|
| February 9, 2021 |
EXHIBIT 10.2 GUARANTOR JOINDER AGREEMENT This Guarantor Joinder Agreement (this “Agreement”) dated as of December 18, 2020 is made by each of the parties on Schedule I hereto (the “Additional Guarantors”), in favor of JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”) for the Lenders under the Credit Agreement referred to below. RECITALS WHEREAS, refe |
|
| February 9, 2021 |
EXHIBIT 10.3 GUARANTOR JOINDER AGREEMENT This Guarantor Joinder Agreement (this “Agreement”) dated as of December 18, 2020 is made by each of the parties on Schedule I hereto (the “Additional Guarantors”), in favor of JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”) for the Lenders under the Credit Agreement referred to below. RECITALS WHEREAS, refe |
|
| February 9, 2021 |
Letter Re: Unaudited Interim Financial Information. Exhibit 15.1 LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION Shareholders and Board of Directors STERIS plc We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated February 9, 2021 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for th |
|
| February 9, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| February 9, 2021 |
EXHIBIT 10.6 GUARANTY SUPPLEMENT December 17, 2020 To the Holders of the Series A-1, A-2, A-3, A-4, A-5, A-6 and A-7 Notes, (each, as hereinafter defined) of STERIS Limited (the “Company”) Ladies and Gentlemen: WHEREAS, in order to refinance certain debt and for general corporate purposes, the Company entered into that certain Amended and Restated Note Purchase Agreement, dated as of March 5, 2019 |
|
| February 3, 2021 |
Filed by STERIS plc Commission File No.: 001-38848 Pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Cantel Medical Corp. Commission File No.: 001-31337 Date: 02/03/2021 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION This communication contains forward-looking statements within the meaning of the federal securities laws about STERIS, Cantel and the prop |
|
| February 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| February 3, 2021 |
Filed by STERIS plc Commission File No.: 001-38848 Pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Cantel Medical Corp. Commission File No.: 001-31337 Date: 02/03/2021 TO: Cantel Employees FROM: STERIS President & CEO Subject: Leadership Succession Planning Dear Cantel Employees: It has been almost a month since we announced our intention to combine our two compa |
|
| February 3, 2021 |
STERIS Announces Leadership Succession Plan EX-99.1 Exhibit 99.1 STERIS Announces Leadership Succession Plan • Walt Rosebrough to step down as CEO at the upcoming Annual General Meeting • Chief Operating Officer, Dan Carestio, to succeed as President and CEO DUBLIN, IRELAND - (February 3, 2021) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that Walt Rosebrough, President and CEO, has announced his intention to step do |
|
| February 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2021 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission |
|
| February 2, 2021 |
STERIS Announces Financial Results for Fiscal 2021 Third Quarter EX-99.1 2 ste12312020ex991.htm EX-99.1 Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2021 Third Quarter • Third quarter revenue increases 4% as reported; 1% constant currency organic • Third quarter earnings per diluted share increase to $1.33 on a U.S. GAAP basis and $1.73 on an adjusted basis • Increased free cash flow driven by net income growth and working capital improvements DUB |
|
| January 22, 2021 |
Exhibit 3 JOINT FILING AGREEMENT We, the undersigned, hereby express our agreement that the attached Schedule 13D is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934. |
|
| January 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 CANTEL MEDICAL CORP. |
|
| January 13, 2021 |
1-877-FACTSET www.callstreet.com Total Pages: 12 Copyright © 2001-2021 FactSet CallStreet, LLC 13-Jan-2021 STERIS Plc (Ireland) (STE) JP Morgan Healthcare Conference Filed by STERIS plc Commission File No.: 001-38848 Pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Cantel Medical Corp. Commission File No.: 001-31337 Date: January 01/13/2021 Corrected Transcript ST |
|
| January 13, 2021 |
Corrected Transcript Total Pages: 17 12-Jan-2021STERIS Plc (Ireland) (STE)Acquisition of Cantel Medical Corp by STERIS plc Call 1-877-FACTSET www. |
|
| January 12, 2021 |
Exhibit 99.4 Dear Cantel Employees: As you have heard from your leadership team, we have announced our intention to acquire Cantel. I know that announcements like this can cause significant stress and anxiety for the people of both companies, and it doesn’t help that we will not have many details until closing. I am writing today to do my best to ease your mind about the Company you will be joinin |
|
| January 12, 2021 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among STERIS plc, Solar New US Holding Co, LLC, Crystal Merger Sub 1, LLC and Cantel Medical Corp. dated as of January 12, 2021 TABLE OF CONTENTS Page ARTICLE I THE MERGERS 5 Section 1.1 The Mergers 5 Section 1.2 Closing 6 Section 1.3 Effective Times 7 Section 1.4 Governing Documents 8 Section 1.5 Officers, Directors and Managers of |
|
| January 12, 2021 |
Exhibit 10.1 EXECUTION VERSION VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), is dated as of January 12, 2021 (the “Effective Date”), by and among STERIS plc, a company incorporated under the laws of Ireland (“Parent”), Solar New US Holding Co, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (“US Holdco”), Crystal Merger Sub 1, |
